tiprankstipranks
Advertisement
Advertisement

UPB Stock Latest News

Upstream Bio management to meet with Piper Sandler
The FlyUpstream Bio management to meet with Piper Sandler
9d ago
UPB
Upstream Bio presents new responder analyses from VIBRANT trial of verekitug
PremiumThe Fly
Upstream Bio presents new responder analyses from VIBRANT trial of verekitug
12d ago
UPB
Upstream Bio downgraded to Neutral from Overweight at JPMorgan
PremiumThe Fly
Upstream Bio downgraded to Neutral from Overweight at JPMorgan
14d ago
UPB
Upstream Bio Shareholders Elect Directors, Ratify 2026 Auditor
PremiumCompany Announcements
Upstream Bio Shareholders Elect Directors, Ratify 2026 Auditor
16d ago
8K
UPB
Upstream Bio initiated with a Buy at H.C. Wainwright
PremiumThe Fly
Upstream Bio initiated with a Buy at H.C. Wainwright
23d ago
UPB
Upstream Bio Maintained at Buy as Verekitug’s Differentiated Efficacy Supports Steady $42 Price Target
PremiumRatingsUpstream Bio Maintained at Buy as Verekitug’s Differentiated Efficacy Supports Steady $42 Price Target
1M ago
UPB
Upstream Bio presents data from Phase 2 VIBRANT trial of verekitug
Premium
The Fly
Upstream Bio presents data from Phase 2 VIBRANT trial of verekitug
1M ago
UPB
Upstream Bio price target lowered to $50 from $51 at Mizuho
Premium
The Fly
Upstream Bio price target lowered to $50 from $51 at Mizuho
1M ago
UPB
Yaron Werber Reiterates Buy Rating on Verekitug Developer, Citing Differentiated TSLP Profile, Streamlined Late‑Stage Path, and Cash Runway Through 2027
PremiumRatings
Yaron Werber Reiterates Buy Rating on Verekitug Developer, Citing Differentiated TSLP Profile, Streamlined Late‑Stage Path, and Cash Runway Through 2027
1M ago
UPB
Upstream Bio reports Q1 revenue $1.03M, consensus $347,170
PremiumThe Fly
Upstream Bio reports Q1 revenue $1.03M, consensus $347,170
1M ago
UPB
Upstream Bio to present new data from Phase 2 Vibrant trial of Verekitug
PremiumThe Fly
Upstream Bio to present new data from Phase 2 Vibrant trial of Verekitug
2M ago
UPB
3 Best High-Risk, High-Reward Stocks to Buy Now, According to Analysts – 4/9/2026
PremiumMarket News
3 Best High-Risk, High-Reward Stocks to Buy Now, According to Analysts – 4/9/2026
3M ago
UPB
AIOT
Validating the IL-13/TSLP Axis: Upstream Bio’s Verekitug Positioned for Differentiated Asthma Efficacy and Favorable Risk–Reward
PremiumRatingsValidating the IL-13/TSLP Axis: Upstream Bio’s Verekitug Positioned for Differentiated Asthma Efficacy and Favorable Risk–Reward
3M ago
UPB
VALIANT Asthma Trial Update: What Upstream Bio’s Phase 2 Milestone Means for Investors
Premium
Company Announcements
VALIANT Asthma Trial Update: What Upstream Bio’s Phase 2 Milestone Means for Investors
3M ago
UPB
Midday Fly By: Carnival cuts forecast on fuel cost, Novartis to buy Excellergy
Premium
The Fly
Midday Fly By: Carnival cuts forecast on fuel cost, Novartis to buy Excellergy
3M ago
U
CG
Wix downgraded, TripAdvisor upgraded: Wall Street’s top analyst calls
PremiumThe Fly
Wix downgraded, TripAdvisor upgraded: Wall Street’s top analyst calls
3M ago
TW
AGX
Upstream Bio downgraded to In Line from Outperform at Evercore ISI
PremiumThe Fly
Upstream Bio downgraded to In Line from Outperform at Evercore ISI
3M ago
UPB
Upstream Bio Launches $150 Million At-The-Market Program
PremiumCompany Announcements
Upstream Bio Launches $150 Million At-The-Market Program
3M ago
8K
UPB
Upstream Bio Initiated at Buy: Verekitug’s Quarterly Dosing Strategy Positions It for Potential Best-in-Class Efficacy vs. TSLP Competitors
PremiumRatings
Upstream Bio Initiated at Buy: Verekitug’s Quarterly Dosing Strategy Positions It for Potential Best-in-Class Efficacy vs. TSLP Competitors
3M ago
UPB
Verekitug’s Differentiated Long-Interval Dosing and Late-Stage Pipeline Position It as a Potential Respiratory Blockbuster
PremiumRatingsVerekitug’s Differentiated Long-Interval Dosing and Late-Stage Pipeline Position It as a Potential Respiratory Blockbuster
3M ago
UPB
Buy Rating Backed by VALIANT Phase 2 Asthma Data and Differentiated, Infrequent-Dosing Profile for Verekitug
Premium
Ratings
Buy Rating Backed by VALIANT Phase 2 Asthma Data and Differentiated, Infrequent-Dosing Profile for Verekitug
3M ago
UPB
Is UPB a Buy, Before Earnings?
Premium
Pre-Earnings
Is UPB a Buy, Before Earnings?
3M ago
UPB

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >